ML281

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

ML281 是一种有效的选择性 STK33 抑制剂，IC50 为 14 nM。

ML-281 is a potent ans selective STK33 inhibitor (IC50 = 14 nM). ML281 showed low nanomolar inhibition of purified recombinant STK33 and a distinct selectivity profile as compared to other STK33 inhibitors. ML281 is a valuable addition to small-molecule probes of STK33. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most mutated oncogene, and KRAS mutations have been found in up to 20% of all human tumors. STK33 was selectively toxic to KRAS-dependent cancer cell lines, suggesting that small-molecule inhibitors of STK33 might selectively target KRAS-dependent cancers.

Cell Viability Assay Cell Line:NCI-H446 cells Concentration:10 μM Incubation Time:72 hours Result:Suppressed cell viability of NCI-H446 cells.

——

ML-281 | ML-281 | ML281

Others

Other Targets

STK33

Cancer

——

1404437-62-2

389.47

C22H19N3O2S

>98% (HPLC)

DMSO : ≥ 30 mg/mL. 77.03 mM; H2O : < 0.1 mg/mL

O=C(c1cccs1)Nc1ccc(C(C)C)cc1c1nc2c(cccc2)[nH]c1=O

N-[2-(3,4-Dihydro-3-oxo-2-quinoxalinyl)-4-(1-methylethyl)phenyl]-2-thiophenecarboxamide

(-20℃)

With Ice Pack

≥ 2 years